Polymer carriers for anticancer drugs targeted to EGF receptor
Language English Country Germany Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- ErbB Receptors metabolism MeSH
- Polymethacrylic Acids chemical synthesis chemistry therapeutic use MeSH
- Drug Delivery Systems methods MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Oligopeptides genetics metabolism MeSH
- Positron-Emission Tomography MeSH
- Antineoplastic Agents chemistry metabolism MeSH
- Flow Cytometry MeSH
- Spectrophotometry, Ultraviolet MeSH
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Duxon MeSH Browser
- ErbB Receptors MeSH
- Polymethacrylic Acids MeSH
- Oligopeptides MeSH
- Antineoplastic Agents MeSH
A novel actively targeted polymer carrier for anticancer drugs based on an N-(2-hydroxypropyl)methacrylamide copolymer (PHPMA) is proposed. An oligopeptide sequence GE7, attached to the polymer, is a specific ligand for the EGF receptor overexpressed on most tumor cells. Co-attachment of selected chemotherapeutics will therefore lead to formation of tumor-specific polymer therapeutics, further enhanced by the EPR effect. FACS measurements prove elevated binding activity of the fluorescently labeled PHPMA/GE7 conjugate in EGFR-rich cells (FaDu, MCF-7), compared to conjugates of scrambled peptides. Cell lines with low EGFR level (SW620, B16F10) bind the GE7 conjugate significantly less.
References provided by Crossref.org
